Sonnet Biotherapeutics Holdings, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Sonnet BioTherapeutics Holdings, Inc. has adjourned its special meeting of stockholders to allow more time for voting on a proposed business combination.
Sonnet BioTherapeutics is set to merge with Hyperliquid Strategies Inc. (Pubco), transforming into a digital asset treasury company focused on HYPE tokens, with existing Sonnet shareholders receiving Pubco common stock and contingent value rights.
Sonnet BioTherapeutics Holdings, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on September 26, 2025, to vote on director elections, executive compensation, auditor ratification, and other key governance matters.
DEF 14A: Sonnet BioTherapeutics Seeks Stockholder Approval for Reverse Stock Split and Equity Issuance
Sonnet BioTherapeutics is asking stockholders to approve a reverse stock split and the issuance of more than 20% of its common stock to Chardan Capital Markets to maintain its Nasdaq listing and secure funding.